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. This is an open access article under1. Introduction
Chronic, immune-mediated diseases (IMDs) represent a heteroge-
neous group of multifactorial disorders [1–3]. It comprises ankylosing
spondylarthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(MS), systemic lupus erythematodes, Behçet's disease, andmany others
[3,4]. IMDs constitute the third-greatest burden for clinical treatment,
after cardiovascular diseases and cancer [5]. In IMDs the combined ef-
fects of a polygenetic predisposition and environmental inﬂuences
eventually induce chronic and self-perpetuating inﬂammation that re-
sult in damage to organs, tissues, or cells.Whilemuch of the knowledge
about immunological disorders is based on murine disease models, the
pathomechanisms of human IMDs are still incompletely resolved. The
strongest genetic association is seen with certain HLA alleles but the
role of the HLA polymorphisms in disease pathogenesis has remained
mysterious, because the extensive linkage disequilibrium within the
major histocompatibility complex (MHC) did not allow for a precise
risk allocation to a particular gene. Although being viewed as autoim-
mune or autoimmune-related in nature, ﬁnal evidence of the autoim-
mune character of most IMDs is missing because precise target cells or
autoantigens of the suspected autoimmune responses are still un-
known. Accordingly, it has remained largely elusive how genetic traits
cooperate with innate and adaptive immune mechanisms in driving
IMD manifestation [4,6,7]. Recent insights into the pathomechanisms
of psoriasis now provide evidence that the disease-associated HLA al-
leles represent the key for resolving both missing heritability andmiss-
ing autoantigens. This allows for redeﬁning the pathogenetic concepts
of HLA-associated IMDs.
2. IMDs: missing heritability
2.1. Familial clustering and genome-wide association studies
Familial clustering and the concordance rate in monozygotic twins
indicate that IMDs have a heritable etiology. Unlike rare monogenic au-
toimmune disease syndromeswith highly penetrantmutations, howev-
er, IMDs are multifactorial [8–10]. They involve the interaction of
individual genotypes with environmental, infectious and lifestyle fac-
tors [11]. Initially, identiﬁcation of disease risk genes was based on can-
didate gene analyses and family-based linkage studies [12]. Completion
of the Human Genome Project and International HapMap Project and
the introduction of array based approaches then facilitated a hypothe-
sis-free survey of the human genome for gene variants associated
with disease susceptibility [12–15]. For each IMD, genome-wide associ-
ation studies (GWAS) revealed a complex genetic predisposition and
identiﬁed numerous disease-associated gene loci [12,13,16]. The
Major Histocompatibility Complex (MHC) region on human chromo-
some 6, which harbours the HLA alleles, stands out as the most promi-
nent susceptibility locus for all IMDs [12,17]. Outside the MHC region,
GWAS revealedmainly common gene variantswhich exert onlymodest
individual effects, explain only a small proportion of familial disease
clustering and ostensibly act independently [18]. Only for a few associ-
ation signals has the causal gene been identiﬁed, and for even fewer
have the causal variant and underlying mechanism been deﬁned.
While some of the susceptibility loci outside the MHC appear to be dis-
ease- or phenotype-speciﬁc, many others are shared across IMDs and
implicate similar susceptibility pathways in multiple diseases [12,13,
19–22]. For particular IMDs 70 or more non-HLA risk loci were identi-
ﬁed. They result in small increments with additive effects for disease
risk but overall still explain only a minor proportion of the familial in-
heritance. Together the allelic variants usually make up for 20% to 50%
of heritability [23]. Thus, despite compelling genetic insights, much of
the genetic contribution to complex traits remains unresolved. Pro-
posed explanations for the missing heritability include that the effect
size of common genevariantsmaybe too small to be detected in cohorts
with limited sample size, or that rare disease alleles are not covered by
GWAS. Furthermore, non-additive epistatic gene-gene interactions
might generate greater-than expected risk effects [13,24]. Polygenic dis-
orders are therefore mainly interpreted as quantitative traits where the
additive effects of hundreds of risk loci with moderate risk size accountfor a substantial part of inheritance [25–27]. Because the identiﬁed asso-
ciations are neither necessary nor sufﬁcient for causing disease, and pa-
tient populations in any disease are inevitably heterogeneous [19,28,29]
it has been doubted, if single genes explaining a large proportion of her-
itability for complex diseases exist at all [24].
2.2. HLA-association: the strongest genetic signal in IMDs
This conclusion turns the attention back to the HLA association of
IMDs. Few, if any genetic signals of IMDs are stronger than the associa-
tions with the human MHC [13,30]. This reﬂects the HLA association of
IMDs that has been known for more than 4 decades: Virtually all auto-
immune conditions are found in association with particular HLA-class
I or class II alleles or both if large enough cohorts are being studied
[17,31–33]. The HLA alleles are localized in the MHC on chromosome
6p21. They are extremely polymorphic. By 2017 there are more than
16.000 HLA and related alleles described by the HLA nomenclature,
comprising more than 12,000 HLA-class I alleles and 4200 HLA-class II
alleles (IPD-IMGT/HLA Database). In view of this exceptionally high di-
versity it is particularly remarkable that only select HLA alleles are
linked with autoimmune diseases: While IMDs share many of the
non-HLA loci, the associated HLA class I and/or class II alleles are usually
disease-speciﬁc [34]. This pleads for a direct causal role in IMD
pathogenesis.
The density of genes and the strong linkage disequilibrium within
theMHC aswell as the lacking functional implementation of disease-as-
sociated HLA alleles have hitherto thwarted an identiﬁcation of the pre-
cise role of particular HLA molecules in IMD susceptibility. Only few
experimental reports have assigned particularHLA-moleculeswith a di-
rect role in disease pathogenesis. Transgenic expression of HLA-
DRB1*1501, the main MS risk allele, caused a T-cell mediated MS-like
disease inmice [35]. Humanizedmice expressing anotherMS risk allele,
HLA-A*03:01, and an HLA-A*03:01-restricted myelin proteolipid pro-
tein-speciﬁc T-cell receptor (TCR) isolated fromMS patients developed
a disease resembling human MS [36,37]. Occurrence of arthritis in rats
or mice transgenic for HLA-B27:05, the main risk allele for ankylosing
spondylitis, indicated that the encoded HLA proteins and not genes in
linkage disequilibriumwithHLA-B27 are responsible for joint inﬂamma-
tion [38–40]. Because HLA-B27 molecules present peptides from cyto-
plasmic proteins on the cell surface [41,42] and act as restriction
elements for CD8+ T-cell responses [43,44] it was proposed that HLA-
B27 may induce autoimmune responses through presentation of
arthritogenic self-peptides. Aberrant cell-surface expression of HLA-
B27 heavy chain homodimers or HLA-B27 misfolding inside the endo-
plasmic reticulum were considered as alternative causes for innate im-
mune dysregulation [45,46]. Yet, despite these intense investigations
the pathogenic mechanisms by which HLA alleles cause disease
remained elusive.
3. Challenges from HLA antigen presentation and TCR antigen
recognition
3.1. HLA antigen presentation and autoimmune responses
The natural immunological function of HLA molecules is presenta-
tion of peptide antigens to the TCRs for cognate antigen recognition by
T cells [47,48]. HLA polymorphisms mostly refer to pockets of the pep-
tide binding groovewhich determines the peptide repertoires by specif-
ic acceptor sites or pockets that bind side chains of particular amino
acids localized at certain positions within the peptide. The peptide res-
idues in between the anchor amino acids may be ﬂexibly occupied. A
single HLA molecule can theoretically display between 6 × 205–7 (HLA
class I) and 12 × 2010 (HLA class II) different peptides [47,49,50]. Differ-
ent HLA molecules select different peptide repertoires for presentation
[51,52], although the binding speciﬁcities may overlap [53,54]. Accord-
ingly, induction of T-cell mediated autoimmune responses through
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most straightforward explanation for the HLA association of IMDs [55].
HLA-class I- and II-molecules differ regarding their expression pat-
terns and the origin and length of the peptide antigens they present.
This should have essential consequences for potential autoimmune re-
sponses. HLA-class I molecules are expressed on all nucleated cells.
They present peptide antigens of usually 8–10 amino acid lengths to
αβ TCRs of CD8+ T cells [56]. The peptides are derived from intracellu-
lar, i.e. cytoplasmic proteins generated within cells that were degraded
by the proteasome, translocated into the endoplasmic reticulum and
subjected to N-terminal trimming by the endoplasmic reticulum pepti-
dases 1 and 2 (ERAP1/2) [56–58]. This reﬂects the primary role of
HLA-class I-molecules to present antigens from viruses that replicate in-
tracellularly within infected cells and otherwise would escape immune
recognition [47]. Consequently, an HLA-class I-restricted autoimmune
response by CD8+ T cells should be directed against a particular target
cell expressing the proteinwhich is the source of the autoantigenic pep-
tide [57,58]. Expression of HLA-class II molecules is mostly restricted to
professional antigen-presenting cells including macrophages, dendritic
cells and B cells [57]. HLA-class II-molecules screen the environment
for antigenic danger signals. The antigenic peptides are primarily de-
rived from extracellular proteins degraded in the endocytic pathway.
They have a 9-amino acid core but the peptides vary greatly in length,
because the ﬂanking residues may extend out of the HLA-class II-bind-
ing groove and [59]. HLA-class II-antigen presentation activates CD4+
T cells which promote inﬂammation and antibody formation. Hence,
HLA-class II-associated autoimmune diseases are usually characterized
by formation of autoantibodies [60]. Unlike HLA-class I-presented cyto-
plasmic antigens, which should be derived from the proteome of a par-
ticular cell, neither source nor length of autoantigens for CD4+ T cells
can be anticipated.
3.2. TCR antigen recognition and polyspeciﬁcity
The TCRs of pathogenic T cells hold the clue to deﬁning the role of
HLA alleles in autoimmune diseases. They determine both HLA-restric-
tion and antigen speciﬁcity and thus deﬁne the precise reactivity of
adaptive immune responses. A T-cell mediated immune response be-
gins with the formation of a trimolecular complex between the TCR of
a T cell and a peptide presented by the appropriate HLA molecule.
Upon antigen recognition, T cells become activated and undergo clonal
expansion at the site of antigen exposure. Due to TCR diversity, any two
T cells expressing the same TCR likely arose from a common progenitor
T cell [7]. TCR clonotypes designate the T cells involved in pathogenic
circumstances that have expanded in response to local antigen stimula-
tion [7,61]. Clonal T-cell expansions characterize inﬂammatory inﬁl-
trates of IMDs such as MS, ankylosing spondylitis, coeliac disease,
Crohn's disease, rheumatoid arthritis, and type I diabetes mellitus
[62–72]. The TCR clonotypes from tissue inﬁltrates can be used for
analysing HLA restriction and antigen speciﬁcity of pathogenic T-cell re-
sponses. As several aspects limit the availability and experimental use of
pathogenic T cells in human diseases, such approaches currently rely
mainly on cloned TCRs [7]. This requires identiﬁcation and isolation of
the clonally expanded pathogenic T cells from complex inﬂammatory
inﬁltrates and analysis of their TCR rearrangements.
Conventional T cells express uniqueαβ TCRs composed of anα- and
β-chain, each generated by somatic recombination of diverse V(D)J
gene segments and randomaddition or deletion of nucleotides at the re-
combination sites [73]. The comparatively small size of the human TCR
repertoire of an estimated 107 to 108 differentαβ TCRs [61], which faces
the huge peptide antigen diversity presented byHLAmolecules, is com-
pensated by the fact that TCRs are polyspeciﬁc [49,50,74–76]. A single
TCR can recognizes more than one million distinct decamer peptides
in the context of a single HLA-class I molecule once they share amino
acid anchor and TCR contact residues deﬁning them as TCR ligands
[77]. While this principle guarantees the recognition of a broad antigenspectrum it creates amajor challenge for antigen identiﬁcation: the pre-
cise peptide antigen of a pathogenic autoimmune response has to be
unequivocally identiﬁed from the universe of potential TCR ligands
[76,77]. In this context HLA-class I-associated IMDs may offer advan-
tages over HLA-class II-risk genes. The origin of HLA-class I-presented
molecules from cytoplasmic proteins limits the spectrum of potential
autoantigens to the target cell proteome. This makes the identiﬁcation
of the target cells of HLA-class I-restricted autoimmune responses an es-
sential precondition. The ﬁrst HLA-class I-associated IMD, in which re-
solving this experimental challenge successfully determined the role
of the main HLA risk gene, deﬁned the autoimmune target cell type
and identiﬁed an autoantigen by using a pathogenic TCR, is psoriasis
vulgaris [78].
4. HLA-C*06:02 and T-cell responses in psoriasis
4.1. HLA-C*06:02 and CD8+ T cells in psoriasis
Psoriasis vulgaris [MIM177900] is a common inﬂammatory skin dis-
ease characterized by T-cell driven epidermal hyperplasia. T cells inﬁl-
trating psoriasis skin lesions display a T-helper/cytotoxic cell (Th/c) 17
phenotype and drive psoriatic inﬂammation through a complex cyto-
kine pattern with the signature cytokines interleukin (IL)-17A, IL-22
and IFN-γ [79,80]. Psoriasis is multifactorial and has a complex genetic
predisposition.HLA-C*06:02 is themajor psoriasis risk gene in Caucasian
populations [81–83]. It is located in the psoriasis susceptibility locus 1
within theMHC on chromosome 6 (PSORS1 on 6p21.3), which accounts
for approximately 50% of disease risk [84–86]. Other psoriasis associated
HLA variants with lesser Odds ratios are HLA-C*07:04, HLA-C*12:03,
HLA-B*27, HLA-B*57, HLA-B amino acid positions 67 and 116, HLA-A
amino acid position 95, and HLA-DQA1 amino acid position 53, and
others [82,87,88]. Psoriasis heritability explained byGWAS variants out-
side theMHCwas estimated at about 20% [89], while the remaining 30%
of disease risk are attributed to environmental factors [90].HLA-C*06:02
deﬁnes familial clustering, early onset and a more severe course of pso-
riasis [91–93]. Accordingly, HLA-C*06:02 is a paradigmatic HLA-risk
gene.
The HLA-C*06:02 association of psoriasis would be consonant with
the presentation of self-antigens to pathogenic CD8+ T cells. Indeed,
CD8+ T cells play a prominent role in psoriasis. The formation of psori-
asis lesions depends on the epidermal inﬂux, activation and clonal ex-
pansion of CD8+ T cells, which predominate the epidermal inﬁltrate
and preferentially rearrange Vβ3 or VB13S1 TCR genes [94–98]. Togeth-
er with the persistence or reappearance of the same clonal T cells in
chronic or relapsing psoriasis lesions [99,100] and sharing of lesional
TCRs between monozygotic twins concordant for psoriasis [101] these
ﬁndings emphasize that dominant tissue autoantigens drive lesional
psoriatic T-cell activation and inﬂammation. Accordingly, understand-
ing the immunopathogenesis of psoriasis demanded answers to two
fundamental but tightly linked issues: What is the role of themain pso-
riasis risk gene, HLA-C*06:02, and which are the antigens of the lesional
psoriatic CD8+ T-cell response?
4.2. Use of a TCR hybridoma to identify the target cells of the psoriatic
autoimmune response
We had addressed these two issues by the use of a paradigmatic
pathogenic psoriatic Vα3S1/Vβ13S1 TCR. It had been obtained by sin-
gle-cell TCR analysis fromapervasive epidermal CD8+T-cell clone iden-
tiﬁed in the lesional inﬁltrate of an HLA-C*06:02-positive psoriasis
patient [95]. The Vα3S1/Vβ13S1 TCR was expressed as recombinant
TCRs along with human CD8 α and β chains in an NFAT-sGFP T-hybrid-
oma cell line that reports on TCR signalling by robust sGFP expression
[102,103]. Consequently, this functional TCR hybridoma carried the
speciﬁcity of the lesional psoriatic T-cell response. The reactivity of the
Vα3S1/Vβ13S1 TCR was characterized in a two-armed strategy: arm I
Table 1
Major non-MHC psoriasis GWAS loci in European and Chinese populations [89,118–129].
Affected pathways Genes/loci
Innate
immunity
IFN signalling ELMO1, TYK2, SOCS1, IFIH1/MDA5,
RNF114, IRF4, RIG1/DDX58,
IFNLR1/IL28RA, IFNGR2
NFκB signalling TNFAIP3, TNIP1, TYK2, REL, NFkBIA,
CARD14, CARM1, UBE2L3, FBXL19
Acquired
immunity
Antigen presentation ERAP1
CD8+ T-cell maturation,
activation and
differentiation
ETS1, RUNX3, TNFRSF9,MBD2, IRF4
Th/c17-differentiation,
IL-23 and IL-17 signalling
pathways
IL23R, IL12B, IL12RB, IL23A, IL23R, TYK2,
STAT3, STAT5A/B, SOCS1, ETS1, TRAF3IP2,
KLF4, IF3
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artiﬁcial peptide ligands of the Vα3S1/Vβ13S1 TCR from combinatorial
peptide libraries, determined the conserved amino acid pattern of
Vα3S1/Vβ13S1-TCR ligands and searched for corresponding peptide
epitopes in the proteome of the target cells. We then combined the re-
sults from both arms and tested the antigenicity of candidate peptide
antigens identiﬁed in arm II in the context of the full-length parent pro-
teins within the target cell type identiﬁed in arm I [78].
These experiments revealed that the Vα3S1/Vβ13S1-TCR reacted
speciﬁcally against melanocytes or melanoma-derived melanocytic
cell lines in an HLA-C*06:02-restricted manner. High frequencies of
CD8+ T cells in direct contact with melanocytes in psoriasis skin lesions
indicated that the Vα3S1/Vβ13S1-TCR reactivity is representative of the
lesional psoriatic T-cell response in general. These CD8+ T cells polar-
ized granzyme B-containing granules towards the melanocyte contact
sites indicating TCR-mediated activation without signs of cytotoxicity
[78,104]. Hence, the unbiased analysis of the lesional psoriatic Vα3S1/
Vβ13S1 TCR had allowed for two fundamental novel insights into psori-
asis pathogenesis: the protein encoded byHLA-C*06:02, the main psori-
asis risk gene, mediates an autoimmune response against melanocytes
as target cells of the lesional psoriatic CD8+ T-cell response.
4.3. HLA-class I-presented autoantigens are determined by antigen
processing
Identiﬁcation of melanocytes as speciﬁc target cells of the HLA-
C*06:02-restricted autoimmune T-cell response in psoriasis provided
the key for identiﬁcation of the causative autoantigen from various an-
tigen candidates. After having determined the conserved amino acid
pattern of peptide ligands recognized by the Vα3S1/Vβ13S1-TCR in
the context of HLA-C*06:02 we searched the transcriptome of melano-
cytes and the human proteome for proteins containing corresponding
peptides. Of approximately 200 self-peptide candidates tested, peptides
from six human proteins stimulated the Vα3S1/Vβ13S1-TCR hybrid-
oma when presented by HLA-C*06:02. In the context of the full-length
parent proteins however, only a peptide epitope from ADAMTS-like
protein 5 (ADAMTSL5) kept its antigenicity for the Vα3S1/Vβ13S1
TCR, and this property depended on expression of the ADAMTSL5-par-
ent protein in melanocytes as psoriatic target cells, but not in other
cell types.
These data document that the human proteome may contain many
peptide antigens that can be recognized by an autoreactive TCR. The ac-
tual immunogenicity of self-peptides, however, is limited by antigen-
processing andmay be cell-type speciﬁc. For presentation under natural
conditions antigenic peptides need to be generated from the full-length
parent protein by proteasomal degradation [58,105]. This involves pre-
ferred proteasomal cleavage sites and cell-type dependent differences
in antigen processing and limits the spectrum of potentially
autoantigenic self-peptides to select proteins and tissues or cell types
[58,106,107]. Accordingly, for ﬁnal validation of HLA-class I-presented
candidate peptide autoantigens the antigenicity of the full-length pro-
tein has to be veriﬁed within the target cell. Only this approach may ﬁ-
nally conﬁrm that a TCR peptide ligand from a natural protein is an
actual autoantigen.
5. Autoimmune disease criteria in psoriasis
In 1993 N. R. Rose and C. Bona had revisited the criteria for establish-
ing the autoimmune etiology of a human disease [108]. In psoriasis,
HLA association [81,83], oligoclonal lymphocytic inﬁltration of the
target organ and restricted TCR Vβ-gene usage [96,98] as well as the
favourable response to immunosuppression [109] represent circum-
stantial evidence. Indirect evidence for an autoimmune pathogenesis
results from triggering psoriasis onset through checkpoint inhibition
[110,111] which may induce various autoimmune-related adverse
drug reactions [112], and from the adoptive transfer or resolution ofpsoriasis by bone marrow or autologous stem cell transplantation
[113–116]. The ﬁndings from the unbiased analysis of a pathogenic pso-
riatic TCR now deﬁne anHLA-restricted autoimmune response as a cen-
tral and disease-speciﬁc event in psoriasis pathogenesis. They show that
the HLA molecule, which is encoded by the main psoriasis risk gene,
HLA-C*06:02, mediates an autoimmune response against melanocytes
through autoantigen presentation. The identiﬁcation of melanocytes
as organ-speciﬁc autoimmune target cells and of ADAMTSL5 as a
melanocytic autoantigen provides direct experimental evidence for
the autoimmunenature of psoriatic inﬂammation. Becausemelanocytes
are a selectively skin-resident cell population and account for 5–10% of
all epidermal cells [117] this also explains why psoriasis primarily tar-
gets the skin.
6. Correlating GWAS results and immune pathomechanisms in
psoriasis
Deﬁning the functional role of HLA-C*06:02 in psoriasis may now
help to understand how gene variants identiﬁed by GWAS may affect
autoimmune disease manifestation and allow for re-deﬁning the archi-
tecture of the pathogenic immune response. GWAS and more targeted
candidate gene approaches have identiﬁedmore than 40psoriasis-asso-
ciated SNPs at a genome wide signiﬁcance level [89,118–129]. Except
for the MHC locus they mostly represent common genetic variants
with low effect size. They can be grouped into genes affecting innate im-
mune pathways, antigen presentation, activation and differentiation of
CD8+ T cells and the IL-23/IL-17 axis (Table 1). Overall, they reﬂect
the different stages of the innate and adaptive immune activation cas-
cade for mounting the CD8+ T-cell response in psoriasis. The following
paragraph brieﬂy summarizes the function of these gene variants and
how theymight impact on the psoriatic autoimmune response. The pre-
cise effects of most GWAS risk loci on biological pathways however, are
still not sufﬁciently clariﬁed and their role remains largely hypothetical.
Because the GWAS results have been extensively discussed in various
reviews [130–135] only speciﬁc aspects related to the focus of thisman-
uscript are addressed here.
6.1. Gene loci related to innate immunity
Initiation, magnitude and quality of adaptive immune responses re-
quire proinﬂammatory signals from the innate immune system [136].
Various psoriatic risk loci point to an increased responsiveness of innate
immunity to trivial or unspeciﬁc triggers, whichmay enhance type-I in-
terferon and NF-κB signalling pathways and hereby promote the initia-
tion of T-cell responses.
IFN-α is a strong activator of adaptive immunity [137]. The initial
phase of psoriasis involves the production of IFN-α by plasmacytoid
dendritic cells [138]. Various candidate gene loci related to type I inter-
feron induction and signalling are associated with psoriasis risk (Table
1). ELMO1 encodes the engulfment and cell motility protein 1 which in-
teracts with DOCK2 and is essential for Toll-like receptor-induced IFN-α
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kine signalling, SOCS1, reduces IFN responses through inhibition of Ty-
rosine kinase 2 (Tyk2)-mediated STAT signalling and negatively
impacts IFN-α receptor 1 surface expression [141]. The ubiquitin bind-
ing protein RNF114 regulates a positive feedback loop that enhances
production of type I IFN induced by cytoplasmic double-stranded RNA
(dsRNA) [142]. DNA sensing by plasmacytoid dendritic cells through
LL37 and endosomal Toll-like receptors is a potent trigger of interferon
production in psoriasis [143]. Proteins encoded by two psoriasis-associ-
ated variants, IFIH1-encoded MDA5 (melanoma differentiation-associ-
ated gene 5) and its paralog retinoic acid-inducible protein 1 (RIG1/
DDX58) are cytoplasmic nucleic acid-sensing receptors which coordi-
nate with each other to evoke downstream signalling events that pro-
mote robust type I-IFN responses and NF-κB activation [144,145].
NF-κB is a key transcription factor in immune responses. NF-κB ac-
tivity is inducible in all cell types and regulates transcription of many
genes which encode cytokines and other proinﬂammatory mediators.
NF-κB is activated by TNF-α and other members of the TNF-α family
[146]. TNF-α blockade is highly effective in psoriasis treatment and
other IMDs [147]. Hyperactivation of NF-κB in skin induces a T-cell de-
pendent psoriatic phenotype in a mouse model of inﬂammation [148].
Various gene variants of the NF-κB pathway contribute to psoriasis
risk (Table 1). TYK2, REL and CARM1 encode proteins essential for NF-
κB activation and signalling [119,149,150]. Proteins encoded by NFKBIA,
FBXL19, UBE2L3, TNIP and TNFAIP3 have inhibitory effects on NF-κB acti-
vation [151–155]. The best characterized variants represent gain of
function mutations in CARD14. CARD14 encodes Caspase recruitmentCD8
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Fig. 1. Model of psoriasis pathogenesis. Select HLA-molecules, in particular HLA-C*06:02, p
autoantigenic peptides, which are generated in melanocytes from cytoplasmic proteins and
HLA-class I molecules is recognized by CD8+ T cells, which have been conditioned for an in
variants related to CD8+ T cell differentiation. In the afferent upstream phase of the melanocy
NF-κB activation induce an increased inﬂammatory response which recruits various immune
proinﬂammatory triggers. In the efferent downstream phase of the autoimmune response g
Tc17 phenotype which promotes psoriatic inﬂammation through the psoriasis signature cytokdomain-containing protein 14 that activates NF-κB. It is the causative
gene at PSORS2 [156,157]. CARD14 ismainly expressed in keratinocytes
and dermal endothelial cells [156,158]. Psoriasis-associated gain-of-
function mutations in CARD14 lead to unopposed NF-κB activation and
transcription of inﬂammatory mediators in keratinocytes in response
to proinﬂammatory triggers or physical injury [156]. The association
with psoriasis but also another inﬂammatory skin disease, Pityriasis
rubra pilaris [159], indicates that CARD14mutations exert an organ-se-
lective proinﬂammatory effect which may precipitate epidermal im-
mune reactions.
6.2. Gene loci related to antigen presentation
All major HLA-class I-associated disorders including ankylosing
spondylitis [160], MS [161], T1D [162] and Behçet's disease [163]
show associations with distinct variants of ERAP1, a gene encoding the
endoplasmic reticulum aminopeptidase 1. ERAP1 governs the ﬁnal
step of peptide antigen generation by N-terminal trimming of antigenic
precursors to the length appropriate for binding to HLA-class I mole-
cules. Different ERAP1 variants show different cleavage activities and
ﬁne substrate preferences and hence may inﬂuence the antigenic pep-
tide repertoire [164–167]. HLA-C*06:02 in psoriasis is found in epistasis
with certain ERAP1 variants [126,168]. A variant protective for psoriasis
reduced the antigenicity of the ADAMTSL5 peptide and melanocytes
(unpublished result). This veriﬁes for a deﬁned autoantigen how the ge-
netic interaction between an HLA-class I allele and ERAP1 variants may
affect disease risk through peptide destruction.IL-17A
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redispose for an autoimmune response against melanocytes through presentation of
trimmed to the appropriate size by certain ERAP1 variants. The complex of peptide and
creased responsiveness during thymic T-cell development under the inﬂuence of gene
te-speciﬁc autoimmune response gene variants related to increased IFN-α signalling and
cells and provides the secondary signals for autoreactive T-cell activation upon unspeciﬁc
ene variants related to the IL-23/IL-17A axis maintain CD8+ T cell differentiation into a
ines IL-17A, IL-17F, IFN-γ and TNF-α and enhanced IL-17A signalling.
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Epidermal inﬁltration, activation and expansion of CD8+ T cells are
key events in psoriasis onset. Various psoriasis risk loci involve genes re-
lated to the generation and differentiation of CD8+ T cells (Table 1). The
transcription factor ETS1 enhances expression of RUNX3. RUNX3 coop-
erates with ETS1 in regulating the development of CD8+ T cells by
repressing CD4 expression and initiating cytotoxic gene expression dur-
ing the differentiation of MHC-class I-restricted thymocytes [169–172].
TNFRSF9 (alternative nomenclature CD137, 4-1BB, ILA) is a member of
the TNF receptor family. It is primarily expressed on activated T cells
and promotes the expansion and memory formation of CD8+ T cells
[173,174]. Methyl-CpG-binding domain protein 2, MBD2, is involved
in the efﬁcient generation of memory effector cells from naïve CD8+ T
cells [175]. Interferon regulatory factor 4 (IRF4) is vital for the expansion
and effector differentiation of CD8+ T cells [176].
6.4. Gene loci related to IL23/T17 pathways
The IL-23/T17 axis has a sentinel role in psoriasis [177]. Blocking IL-
23 or IL-17 has strong efﬁcacy in psoriasis treatment [178–181]. IL-6 and
transforming growth factor β (TGF-β) released by dermal DCs elicit
Retinoic Acid Receptor-RelatedOrphan Receptor Gamma-t (RORγt)-de-
pendent differentiation of naive T cells into Th/c17 cells [182–185]. IL-23
sustains the phenotype and expansion of Th/c17 cells [186]. Psoriasis
susceptibility is associated with SNPs in both subunits of IL-23,
IL12Bp40 and IL23Ap19, in IL23R [124,187,188], TYK2 [126], JAK2 [125]
and STAT3 [89] (Table 1). The IL-23 receptor is a heterodimer composed
of IL-12Rβ1 and IL-23R [189]. A prominent coding SNP in IL23R reduces
IL-23 signalling and is protective against psoriasis and other autoim-
mune diseases [190]. IL-23R associates with Jak2 and STAT3 while IL-
12Rβ1 interacts directly with Tyk2 [189]. Proteins encoded by TYK2,
STAT3, SOCS1, and ETS1 are involved in downstream signalling of IL-23
[191,192]. IL-23 induced activation of STAT3 induces transcription of
IL-17A and IL-17F [193]. STAT3 up-regulates the expression of the
Th17-speciﬁc transcriptional regulator RORγt. A SNP within the gene
for TRAF3 interacting protein 2 (TRAF3IP2) may inﬂuence NF-κB activa-
tion downstream of IL-17 receptor signalling and promote IL-17 in-
duced effects [121,194,195]. Other genes (ZC3H12C, IL12B, STAT5A/5B,
ILF3) refer to Th1 signalling pathways and interleukin 2 expression
[132].
7. The pathogenetic cascade of HLA-associated IMDs
Together these insights propose an HLA-centered pathogenetic
model for psoriasis and other HLA-associated IMDs. In this model a par-
ticular HLA allele represents the causal risk gene. It constitutes the es-
sential disease prerequisite because it predisposes for a tissue- and
antigen-speciﬁc autoimmune response through its capacity for
autoantigen presentation. The HLA allele alone, however, is not sufﬁ-
cient for disease manifestation but requires the additive effects of com-
mon gene variants, which provide the functional environment for
manifestation and differentiation of the actual autoimmune response.
From the perspective of the HLA-C*06:02-restricted T-cell mediated
autoimmune response as central event in psoriasis pathogenesis, the
pathogenic cascade can be differentiated into a proximal afferent and
distal efferent phase (Fig. 1). In the upstream phase gene variants relat-
ed to type-I IFN signalling and NF-κB activation may potentiate the in-
nate immune response to trivial environmental triggers. This may
promote the recruitment of inﬂammatory cells and production of proin-
ﬂammatorymediators and chemokines, providing ample secondary sig-
nals for the HLA-restricted activation of potentially autoreactive non-
cytotoxic CD8+ T cells that may have been conditioned by certain
gene variants during thymic CD8+ T cell development and recognize
peptides generated under the inﬂuence of certain ERAP1 variants. The
efferent downstream phase involves gene variants related to the IL-23/IL-17 axis. They act on the maturation and differentiation of
autoreactive CD8+ T cells into a Tc17 phenotype, which is maintained
by IL-23. Together with enhanced IL-17 signalling, the Tc17 cytokine
pattern promotes keratinocyte hyperplasia, inﬂammation and recruit-
ment of inﬂammatory cells. In this pathogenetic cascade the combina-
tion of particular risk gene activities may determine disease
manifestation and phenotype in a polygenic manner [12]. In a case-
case study HLA-C*06:02 associated equally strong with mild and severe
psoriasis. Strong additive effects for severe diseasewere observedwhen
HLA-C*06:02 combined with gene variants of IL23A, IL23R, IL12B, NFKB1
or TNIP1. Thus, HLA-C*06:02 confers an overall risk for psoriasis, while
gene variants related to innate immune activation and the IL-23/T17
axis may modify disease expression [196].
8. Conclusion
Psoriasis is the ﬁrst major IMD where the pathogenic role of the
mainHLA-risk gene could be unequivocally identiﬁed through the unbi-
ased analysis of a pathogenic TCR. The HLA-C*06:02-restricted
autoreactivity of the Vα3S1/Vβ13S1-TCR obtained directly from tis-
sue-inﬁltrating psoriatic T cells provided direct evidence that disease-
associated HLA-alleles can confer autoimmune susceptibility by facili-
tating tissue-speciﬁc autoimmune responses through presentation of
particular autoantigens. These insights propose a concept for complex
HLA-associated immunemediated disorders, where the genetic predis-
position of IMDs combines a causative HLA-risk allele with the additive
effects of many modiﬁer genes that ﬁnally facilitate disease manifesta-
tion and modulate disease phenotype. This model attributes much of
the missing heritability of IMDs to disease-associated HLA alleles, and
it may inspire attempts to identify the missing autoantigens using sim-
ilar approaches in other IMDs as well. This may ﬁnally allow for the de-
velopment of biomarkers and novel causal therapies.
Take-home messages
• The association of IMDswith particular HLA-allelesmay reﬂect the ca-
pacity of the encoded HLA proteins to present self-peptides and in-
duce an autoimmune response.
• Clonal T-cell expansions within the inﬂammatory tissue inﬁltrate of
IMDs may reﬂect the activation and expansion of pathogenic T cells
through stimulation by local tissue antigens.
• Because HLA-class I-molecules present antigens from cytoplasmic
proteins, anHLA-class I restricted autoimmune response should natu-
rally be directed against a particular target cell type.
• The particular target cell type may deﬁne the organ or tissue which is
affected by the HLA-restricted autoimmune response.
• Identiﬁcation of the autoimmune target cell type may be a prerequi-
site to identify and validate potential autoantigens, because the im-
munogenicity of particular self-proteins may be cell-type dependent.
• Because of TCR polyspeciﬁcity and cell-type speciﬁc differences in an-
tigen processing, for a precise identiﬁcation of disease-relevant HLA-
class I-presented autoantigens it is not sufﬁcient to determine peptide
ligands for select TCRs but necessary to prove the immunogenicity of
the peptide in the context of the parent protein within the target cell.
• The number of autoantigens relevant for an autoimmune disease is
probably much smaller than the broad TCR reactivity against various
natural peptide ligands would predict.
• HLA-allelesmay account for themissing heritability of IMDs and facil-
itate the identiﬁcation of autoimmune target cells and autoantigens.
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